The gastrointestinal (GI) therapeutics industry is on the rise; growing to reach $68,237.0m by 2028. This growth stems from rising prevalence of GI disorders. Moreover, the increase in R&D has been a priority of the big pharma companies to infuse the drug pipelines with a new set of candidates with a high potential of reaching the clinical stage. However, the pricing pressure due to rising competition has hampered the market growth. On the contrary, the expiry of high-profile patents, which will carve the path for the launch of generic drugs in the market can provide growth opportunities to the other players in the market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 263-page report you will receive 116 charts– all unavailable elsewhere.
The 263-page report provides clear detailed insight into the leading 50 gastrointestinal therapeutic companies. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Our study discusses the selected leading companies that are the major players in the gastrointestinal drugs market:
• Abbott
• AbbVie
• Alexion Pharmaceuticals
• Allergan
• ANI Pharmaceuticals, Inc.
• AstraZeneca
• Bayer AG
• Biogen
• Eisai Co., Ltd.
• Eli Lilly
• Evoke Pharma
• GlaxoSmithKline
• Intercept Pharmaceuticals
• Ironwood Pharmaceuticals
• Janssen Pharmaceutica
• Kyowa Hakko Kirin Co. Ltd.
• Mallinckrodt plc
• Pfizer
• Synergy Pharmaceuticals Inc.
• Takeda
• Cadila Healthcare Ltd.
• Novartis AG
• Shire
• Merck & Co., Inc.
• Lexicon Pharmaceuticals, Inc.
• Sanofi
• ETX Pharma, Inc.
• Theravance Biopharma, Inc.
• Other companies
• This report also discusses factors that drive and restrain the market, as well as opportunities in the gastrointestinal therapeutic market.
Visiongain’s study is intended for anyone requiring commercial analyses for the leading 50 gastrointestinal therapeutic companies. You find data, trends and predictions.
Buy our report today Top 50 Gastrointestinal Therapeutic Companies: GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com
1. Report Overview
1.1 Global Gastrointestinal Therapeutics Market Overview
1.2 Market Definition & Scope
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report?
1.6 Key Questions Answered by This Analytical Report
1.7 How This Report Delivers
1.8 Who is This Report For?
1.9 Methodology
1.9.1 Primary Research
1.9.2 Secondary Research
1.9.3 Market Evaluation & Forecasting Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. An Introduction to Gastrointestinal Therapeutics Market
2.1 Gastrointestinal Disorders
2.1.1 Functional gastrointestinal disorders
2.1.1.1 Constipation
2.1.1.2 Irritable Bowel Syndrome (IBS)
2.1.2 Structural gastrointestinal disorders
2.1.2.1 Haemorrhoids
2.1.2.2 Anal fissures
2.1.2.3 Perianal abscesses
2.1.2.4 Anal fistula
2.1.2.5 Diverticular disease
2.1.2.6 Colon polyps and cancer
2.1.3 Colitis
2.2 FDA Approved Drugs for Gastroenterology (2000-2018)
2.2.1 Drugs Approved in 2018
2.2.2 Drugs Approved in 2017
2.2.3 Drugs Approved in 2016
2.2.4 Drugs Approved in 2015
2.2.5 Drugs Approved in 2014
2.2.6 Drugs Approved in 2013
2.2.7 Drugs Approved in 2012
2.2.8 Drugs Approved in 2011
2.2.9 Drugs Approved in 2010
2.2.10 Drugs Approved in 2009
2.2.11 Drugs Approved in 2008
2.2.12 Drugs Approved in 2006
2.2.13 Drugs Approved in 2005
2.2.14 Drugs Approved in 2004
2.2.15 Drugs Approved in 2003
2.2.16 Drugs Approved in 2002
2.2.17 Drugs Approved in 2001
2.2.18 Drugs Approved in 2000
2.3 Market Dynamics
2.3.1 Drivers
2.3.1.1 Rising Disease Prevalence
2.3.1.2 Increase in the Number of Aging Population
2.3.1.3 Increased Demand in Market
2.3.2 Restraints
2.3.2.1 Lengthy & stringent government regulations
2.3.2.2 Competition from Generic Drugs
2.3.3 Opportunities
2.3.3.1 Increase in purchasing power of emerging economies
3. GlaxoSmithKline plc
3.1 Company Overview
3.2 Leadership Team
3.3 Operating Segments
3.4 Gastrointestinal Drugs Product Pipeline
3.5 Key Financials
4. Abbott Laboratories
4.1 Company Overview
4.2 Leadership Team
4.3 Core Therapeutic Areas
4.4 Product Portfolio
4.5 Key Financials
4.6 Recent Major Strategies & Developments
5. Allergan plc
5.1 Company Overview
5.2 Leadership Team
5.3 Product Portfolio
5.4 Key Financials
5.5 Recent Major Strategies & Developments
6. Eli Lilly and Company
6.1 Company Overview
6.2 Leadership Team
6.3 Core Therapeutic Areas
6.4 Product Portfolio
6.5 Key Financials
6.6 Recent Major Strategies & Developments
7. Evoke Pharma, Inc.
7.1 Company Overview
7.2 Leadership Team
7.3 Product Focus
7.3.1 Clinical Milestones of Gimoti
7.3.1.1 Comparative Exposure Pharmacokinetic (PK) Trial
7.3.1.2 Discovery of Sex-Based Pharmacokinetic Differences
7.3.1.3 Completed Phase 3 clinical trial
7.4 Key Financials
7.5 Recent Major Strategies & Developments
8. Janssen Pharmaceutica N.V. (Company of Johnson & Johnson)
8.1 Company Overview
8.2 Leadership Team
8.3 Core Therapeutic Areas
8.4 Product Porfolio
8.4.1 Immunology
8.5 Key Financials
8.6 Recent Major Strategies & Developments
9. Takeda Pharmaceutical Company Limited
9.1 Company Overview
9.2 Leadership Team
9.3 Core Therapeutic Areas
9.4 Key Financials
9.5 Recent Major Strategies & Developments
10. Alexion Pharmaceuticals Inc.
10.1 Company Overview
10.2 Leadership Team
10.3 Core Therapeutic Areas
10.4 Product Portfolio
10.5 Key Financials
11. AstraZeneca PLC
11.1 Company Overview
11.2 Leadership Team
11.3 Core Therapeutic Areas
11.4 Gastrointestinal Drugs Product Pipeline
11.5 Product Portfolio
11.6 Key Financials
11.7 Recent Major Strategies & Developments
12. Biogen Inc.
12.1 Company Overview
12.2 Leadership Team
12.3 Core Therapeutic Areas
12.4 Product Portfolio
12.5 Key Financials
13. Intercept Pharmaceuticals, Inc.
13.1 Company Overview
13.2 Leadership Team
13.3 Core Therapeutic Areas
13.4 Product Portfolio
13.5 Key Financials
13.6 Recent Major Strategies & Developments
14. Ironwood Pharmaceuticals, Inc.
14.1 Company Overview
14.2 Leadership Team
14.3 Gastrointestinal Drugs Product Pipeline
14.4 Product Portfolio
14.5 Key Financials
14.6 Recent Major Strategies & Developments
15. Mallinckrodt plc
15.1 Company Overview
15.2 Leadership Team
15.3 Therapeutic Areas
15.4 Product Portfolio
15.5 Key Financials
15.6 Recent Major Strategies & Developments
16. Pfizer Inc.
16.1 Company Overview
16.2 Leadership Team
16.3 Therapeutic Area
16.4 Product Portfolio
16.5 Key Financials
16.6 Recent Major Strategies & Developments
17. ANI Pharmaceuticals, Inc.
17.1 Company Overview
17.2 Leadership Team
17.3 Product Portfolio
17.4 Key Financials
17.5 Recent Major Strategies & Developments
18. Eisai Co., Ltd.
18.1 Company Overview
18.2 Leadership Team
18.3 Product Pipeline
18.4 Operating Segments
18.5 Product Portfolio
18.6 Key Financials
18.7 Recent Major Strategies & Developments
19. AbbVie Inc.
19.1 Company Overview
19.2 Leadership Team
19.3 Core Therapeutic Areas
19.4 Product Portfolio
19.5 Key Financials
20. Synergy Pharmaceuticals Inc.
20.1 Company Overview
20.2 Leadership Team
20.3 Core Therapeutic Areas
20.4 Product Pipeline
20.5 Product Portfolio
20.6 Key Financials
20.7 Recent Major Strategies & Developments
21. Bayer AG
21.1 Company Overview
21.2 Leadership Team
21.3 Operating Segments
21.4 Product Portfolio
21.5 Key Financials
21.6 Recent Major Strategies & Developments
22. Kyowa Hakko Kirin Co., Ltd.
22.1 Company Overview
22.2 Leadership Team
22.3 Operating Business
22.4 Product Pipeline
22.5 Product Portfolio
22.6 Key Financials
23. Cadila Pharmaceuticals Limited
23.1 Company Overview
23.2 Leadership Team
23.3 Business Operations
23.4 Product Portfolio
23.5 Key Financials
24. Novartis AG
24.1 Company Overview
24.2 Leadership Team
24.3 Operating Segments
24.4 Product Portfolio
24.5 Key Financials
25. Shire Plc
25.1 Company Overview
25.2 Leadership Team
25.3 Core Therapeutic Areas
25.4 Product Portfolio
25.5 Key Financials
25.6 Recent Major Strategies & Developments
26. Merck & Co., Inc.
26.1 Company Overview
26.2 Leadership Team
26.3 Core Therapeutic Areas
26.4 Product Portfolio
26.5 Key Financials
26.6 Recent Major Strategies & Developments
27. Lexicon Pharmaceuticals
27.1 Company Overview
27.2 Leadership Team
27.3 Core Therapeutic Areas
27.4 Product Portfolio
27.5 Key Financials
27.6 Recent Major Strategies & Developments
28. Sanofi S.A.
28.1 Company Overview
28.1.1 Main changes since 2011
28.2 Leadership Team
28.3 Core Therapeutic Areas
28.4 Product Portfolio
28.5 Key Financials
29. ETX Pharma, Inc
29.1 Company Overview
29.2 Leadership Team
29.3 Product Pipeline
30. Theravance Biopharma, Inc.
30.1 Company Overview
30.2 Leadership Team
30.3 Product Portfolio
30.4 Gastrointestinal Drugs Product Pipeline
30.5 Key Financials
31. Neurogastrx, Inc.
31.1 Company Overview
31.2 Leadership Team
31.3 Product Portfolio
31.4 Recent Major Strategies & Developments
32. Bausch Health Companies Inc.
32.1 Company Overview
32.2 Leadership Team
32.3 Core Therapeutic Areas
32.4 Product Portfolio
32.5 Product Pipeline
32.6 Key Financials
32.7 Recent Major Strategies & Developments
33. Boehringer Ingelheim International GmbH
33.1 Company Overview
33.2 Key Financials
34. Gubra
34.1 Company Overview
34.2 Leadership Team
34.3 Products Portfolio
34.3.1 Gastrointestinal Diseases Partner Programs
34.3.2 Contract research services within GI
34.4 Recent Major Strategies & Developments
35. RedHill Biopharma Ltd.
35.1 Company Overview
35.2 Product Portfolio
35.3 Product Pipeline
35.4 Recent Major Strategies & Developments
36. Astellas Pharma, Inc.
36.1 Company Overview
36.2 Leadership Team
36.3 Therapeutic Areas
36.4 Product Pipeline
36.5 Key Financials
36.6 Recent Major Strategies & Developments
37. AzurRx BioPharma, Inc.
37.1 Company Overview
37.2 Leadership Team
37.3 Business Areas
37.4 Product Pipeline
38. Gilead Sciences, Inc.
38.1 Company Overview
38.2 Leadership Team
38.3 Business Areas
38.4 Product Pipeline
38.5 Key Financials
39. Galapagos NV
39.1 Company Overview
39.2 Leadership Team
39.3 Business Areas
39.4 Key Financials
40. Amgen Inc.
40.1 Company Overview
40.2 Leadership Team
40.3 Product Pipeline
40.4 Key Financials
40.5 Recent Major Strategies & Developments
41. Zeria Pharmaceutical Co., Ltd.
41.1 Company Overview
41.2 Leadership Team
41.3 Product Portfolio
41.4 Key Financials
42. Mitsubishi Tanabe Pharma Corporation
42.1 Company Overview
42.2 Leadership Team
42.3 Product Pipeline
42.4 Product Portfolio
42.5 Key Financials
43. Celgene Corporation
43.1 Company Overview
43.2 Leadership Team
43.3 Business Area
43.4 Product Pipeline
43.5 Product Portfolio
43.6 Key Financials
44. BioLineRx Ltd.
44.1 Company Overview
44.2 Leadership Team
44.3 Product Pipeline
45. Soligenix, Inc.
45.1 Company Overview
45.2 Leadership Team
45.3 Product Pipeline
46. Ono Pharmaceutical Co., Ltd.
46.1 Company Overview
46.2 Leadership Team
46.3 Product Pipeline
46.4 Key Financials
47. Bristol-Myers Squibb Company
47.1 Company Overview
47.2 Leadership Team
47.3 Product Portfolio
47.4 Product Pipeline
47.5 Key Financials
47.6 Recent Development & Strategies
48. Imugene Ltd
48.1 Company Overview
48.2 Leadership Team
48.3 Product Pipeline
48.4 Key Financials
49. Otsuka Pharmaceutical Co., Ltd.
49.1 Company Overview
49.2 Leadership Team
49.3 Business Areas
49.4 Product Pipeline
49.5 Key Financials
50. Oncolytics Biotech, Inc.
50.1 Company Overview
50.2 Leadership Team
50.3 Product Portfolio
51. Lonza Group AG
51.1 Company Overview
51.2 Leadership Team
51.3 Product Portfolio
51.4 Product Portfolio
51.5 Key Financials
52. Array BioPharma Inc.
52.1 Company Overview
52.2 Leadership Team
52.3 Product Pipeline
52.4 Key Financials
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 5.1: Revenue for Gastrointestinal Drugs of Allergan
Table 7.1: Evoke Operating Expenses ($), 2015-2017
Table 8.1: Johnson & Johnson: Pharmaceutical Sales (2015-2017)
Table 18.1: GI R&D Product Pipeline
Table 20.1: GI R&D Product Pipeline
Table 22.1: GI R&D Product Pipeline
Table 24.1: Novartis Operating Segments
Table 24.2: Novartis ($m), 2015-2017
Table 32.1: Bausch Health GI Pipeline (as on 20th Feb 2019)
Table 36.1: Astellas GI Pipeline (as on 20th Feb 2019)
Table 49.1: Otsuka Pharmaceutical Product Pipeline
Table 52.1: Array BioPharma Product Pipeline
List of Figures
Figure 2.1 Ageing Population Estimates 2010 - 2050
Figure 3.1: GSK: Revenue ($m), 2016-2018
Figure 3.2: GSK: Revenue Share (%) by Segment, 2018
Figure 3.3: GSK: Revenue Share (%) by Geography, 2018
Figure 4.1: Abbott Laboratories: Revenue ($m), 2015-2017
Figure 4.2: Abbott Laboratories: Revenue Share (%) by Segment, 2017
Figure 4.3: Abbott Laboratories: Revenue Share (%) by Geography, 2017
Figure 5.1: Allergan: Revenue ($m), 2015-2017
Figure 5.2: Allergan: Revenue Share (%) by Segment, 2017
Figure 6.1: Eli Lilly: Revenue ($m), 2015-2017
Figure 6.2: Eli Lilly: Revenue Share (%) by Segment, 2017
Figure 6.3: Eli Lilly: Revenue Share (%) by Geography, 2017
Figure 8.1: Johnson & Johnson: Revenue ($m), 2015-2017
Figure 8.2: Johnson & Johnson: Revenue Share (%) by Segment, 2017
Figure 8.3: Johnson & Johnson: Revenue Share (%) by Geography, 2017
Figure 9.1: Takeda: Revenue ($m), 2015-2017
Figure 9.2: Takeda: Revenue Share (%) by Segment, 2017
Figure 9.3: Takeda: Revenue Share (%) by Geography, 2017
Figure 10.1: Alexion: Revenue ($m), 2015-2017
Figure 10.2: Alexion: Revenue Share (%) by Segment, 2017
Figure 10.3: Alexion: Revenue Share (%) by Geography, 2017
Figure 10.4: Alexion: Solaris Revenue Share (%) by Geography, 2017
Figure 11.1: AstraZeneca: Revenue ($m), 2015-2017
Figure 11.2: AstraZeneca: Revenue Share (%) by Segment, 2017
Figure 11.3: AstraZeneca: Revenue Share (%) by Geography, 2017
Figure 12.1: Biogen: Revenue ($m), 2015-2017
Figure 12.2: Biogen: Revenue Share (%) by Operations, 2017
Figure 12.3: Biogen: Revenue Share (%) by Geography, 2017
Figure 12.4: Biogen: Revenue Share (%) by Therapeutic Area/Products, 2017
Figure 13.1: Intercept: Revenue ($Thousands), 2015-2017
Figure 13.2: Intercept: Revenue Share (%) by Operations, 2017
Figure 14.1: Ironwood: Revenue ($Thousands), 2015-2017
Figure 14.2: Ironwood: Revenue Share (%) by Operations, 2017
Figure 15.1: Mallinckrodt: Revenue ($m), 2015-2017
Figure 15.2: Mallinckrodt: Revenue Share (%) by Segment, 2017
Figure 15.3: Mallinckrodt: Revenue Share (%) by Geography, 2017
Figure 16.1: Pfizer: Revenue ($m), 2015-2017
Figure 16.2: Pfizer: Revenue Share (%) by Segment, 2017
Figure 16.3: Pfizer: Revenue Share (%) by Geography, 2017
Figure 16.4: Pfizer: Revenue Share (%) by Key Products, 2017
Figure 17.1: ANI Pharmaceuticals: Revenue ($Thousands), 2015-2017
Figure 17.2: ANI Pharmaceuticals: Research & Development Expenditure ($Thousands), 2015-2017
Figure 17.3: ANI Pharmaceuticals: Revenue Share (%) by Segment, 2017
Figure 18.1: Eisai: Revenue ($Million), 2015-2017
Figure 18.2: Eisai: Revenue Share (%) by Segment, 2017
Figure 19.1: AbbVie: Revenue ($m), 2015-2017
Figure 19.2: AbbVie: Revenue Share (%) by Leading Products, 2017
Figure 19.3: AbbVie: Revenue Share (%) by Geography, 2017
Figure 20.1: Synergy: Revenue ($Thousands), 2015-2017
Figure 20.2: Synergy: R&D Spending ($Thousands), 2014-2017
Figure 21.1: Bayer: Revenue ($m), 2015-2017
Figure 21.2: Bayer: Revenue Share (%) by Segments, 2017
Figure 21.3: Bayer: Revenue Share (%) by Geography, 2017
Figure 22.1: Kyowa Hakko Kirin: Revenue ($m), 2015-2017
Figure 22.2: Kyowa Hakko Kirin: Revenue Share (%) by Segments, 2017
Figure 23.1: Cadila Pharmaceuticals: Revenue ($m), 2015-2017
Figure 23.2: Cadila Pharmaceuticals: Revenue Share (%) by Geography, 2017
Figure 24.1: Novartis: Revenue ($m), 2015-2017
Figure 24.2: Novartis: Revenue Share (%) by Division, 2017
Figure 24.3: Novartis: Revenue Share (%) by Geography, 2017
Figure 25.1: Shire: Revenue ($m), 2015-2017
Figure 25.2: Shire: Revenue Share (%) by Segment, 2017
Figure 25.3: Shire: Revenue Share (%) by Geography, 2017
Figure 26.1: Merck: Revenue ($m), 2015-2017
Figure 26.2: Merck: Revenue Share (%) by Business Segment, 2017
Figure 26.3: Merck: Pharmaceuticals Revenue Share (%) by Brand, 2017
Figure 26.4: Merck: Revenue Share (%) by Geography, 2017
Figure 27.1: Lexicon: Loss Incurred ($Thousands), 2015-2017
Figure 28.1: Sanofi: Revenue ($m), 2015-2017
Figure 28.2: Sanofi: Revenue Share (%) by Segment, 2017
Figure 28.3: Sanofi: Revenue Share (%) by Global Business Unit, 2017
Figure 28.4: Sanofi: Revenue Share (%) by Geography, 2017
Figure 30.1: Theravance Biopharma: Revenue ($Thousands), 2016-2018
Figure 30.2: Theravance Biopharma: Revenue Share (%) by Type, 2018
Figure 32.1: Bausch Health: Revenue ($m), 2016-2018
Figure 32.2: Bausch Health: Revenue Share (%) by Segment, 2018
Figure 32.3: Bausch Health: Bausch Health: Revenue Share (%) by Product and by Product Category, 2018
Figure 32.4: Bausch Health: Revenue Share (%) by Geography, 2018
Figure 33.1: Boehringer Ingelheim: Revenue ($bn), 2015-2017
Figure 33.2: Boehringer Ingelheim: Revenue Share (%) by Segment, 2017
Figure 36.1: Astellas: Revenue ($bn), 2016-2018
Figure 33.2: Astellas: Revenue Share (%), By Geography, 2018
Figure 38.1: Gilead Sciences: Revenue ($m), 2016-2018
Figure 39.1: Galapagos: Revenue ($m), 2015-2017
Figure 40.1: Amgen: Revenue ($m), 2016-2018
Figure 40.2: Amgen: Revenue Share (%) by Product, 2018
Figure 40.3: Amgen: Revenue Share (%) by Geography, 2018
Figure 41.1: Zeria: Revenue ($m), 2015-2017
Figure 41.2: Zeria: Revenue Share (%) by Product, 2018
Figure 42.1: Mitsubishi Tanabe Pharma: Revenue ($bn), 2015-2017
Figure 42.2: Mitsubishi Tanabe Pharma: Revenue Share (%) by Business, 2017
Figure 43.1: Celgene: Revenue ($m), 2015-2017
Figure 43.2: Celgene: Revenue Share (%) by Product, 2017
Figure 43.3: Celgene: Revenue Share (%) by Geography, 2017
Figure 46.1: Ono Pharmaceutical: Revenue ($m), 2015-2017
Figure 47.1: Bristol-Meyers: Revenue ($m), 2015-2017
Figure 47.2: Bristol-Meyers: Revenue Share (%) by Geography, 2017
Figure 48.1: Imugene: Revenue ($), 2015-2017
Figure 49.1: Otsuka Pharmaceutical: Revenue ($m), 2015-2017
Figure 51.1: Lonza: Revenue ($m), 2016-2018
Figure 51.2: Lonza: Revenue Share (%) by Segment, 2018
Figure 51.3: Lonza: Revenue Share (%) by Geography, 2018
Figure 52.1: Array BioPharma: Revenue ($m), 2016-2018
Figure 52.2: Array BioPharma: Revenue Share (%) by Geography, 2018
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
